Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Brolucizumab for neovascular age-related macular degeneration holds up in real world
The use of brolucizumab for the treatment of patients with neovascular age-related macular degeneration (nAMD) in the real-world setting appears to be effective and safe, consistent with data from pivotal trials, as reported in a study.
Brolucizumab for neovascular age-related macular degeneration holds up in real world
30 Sep 2022Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
Chronic hepatitis B (CHB) patients, who have virological response with long-term entecavir (ETV) treatment, appear to fare well with a strategy of adding or switching to peginterferon (PEG-IFN) therapy, as shown in a study.
Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
30 Sep 2022Ruxolitinib cream achieves durable itch-free state in atopic dermatitis
Among adults and adolescents with atopic dermatitis (AD), ruxolitinib cream helps sustainably improve itching, reports a recent analysis.
Ruxolitinib cream achieves durable itch-free state in atopic dermatitis
29 Sep 2022SGLT2 inhibitors potentially protective against dry eye disease
Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.
SGLT2 inhibitors potentially protective against dry eye disease
29 Sep 2022Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
29 Sep 2022Renal denervation bounces back in 3-year follow-up study
Following negative primary results, the final follow-up of the SYMPLICITY HTN-3 trial takes a turn for the better, demonstrating significant blood pressure (BP) reductions with renal denervation (RDN) in patients with uncontrolled hypertension (HTN).